Ganciclovir (sodium) (Standard)

Ganciclovir (sodium) (Standard) is the analytical standard of Ganciclovir (sodium) . This product is intended for research and analytical applications. Ganciclovir (BW 759) sodium, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir sodium also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir sodium inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir sodium has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain[1][2][3].

Product Specifications

CAS Number

[107910-75-8]

Product Name Alternative

BW 759 (sodium) (Standard) ; 2'-Nor-2'-deoxyguanosine (sodium) (Standard)

UNSPSC

12352005

Target

Antibiotic; CMV; HSV; Nucleoside Antimetabolite/Analog; Reference Standards

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Others

Field of Research

Infection; Cancer

Smiles

OCC(OCN1C=NC2=C1N=C(N)N=C2O[Na])CO

Molecular Formula

C9H12N5NaO4

Molecular Weight

277.21

References & Citations

[1]Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65 (4) :399-403.|[2]Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39 (4) :597-638.|[3]Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115.|[4]Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23 (1) :5-12.|[5]Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4.|[6]Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39 (3) :189-197.